<p>China's CanSino Biologics Inc said on Sunday that its recently developed Covid-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.</p>.<p>The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.</p>.<p>"The approval will have a positive impact on the company's performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.</p>.<p><strong>Also Read — <a href="https://www.deccanherald.com/business/business-news/softbank-plans-vision-fund-staff-cuts-of-at-least-20-1141638.html" target="_blank">SoftBank plans vision fund staff cuts of at least 20%</a></strong></p>.<p>The company cautioned, however, that it will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials.</p>.<p>China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's Covid-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.</p>.<p>Cansino also said it was uncertain when its vaccine would be able to go to market, since additional administrative approvals are still needed, while sales would depend on the Covid-19 situation at home and abroad, as well as China's vaccination rate.</p>.<p>China has seen a recent flare-up in Covid outbreaks. The southern tech hub of Shenzhen imposed a weekend lockdown in most parts of the city on Saturday, while the southwestern metropolis of Chengdu put its 21 million people under lockdown on Thursday.</p>.<p>Mainland China reported 1,848 new coronavirus cases for September 3, including both symptomatic and asymptomatic infections, compared with 1,988 new cases a day earlier.</p>
<p>China's CanSino Biologics Inc said on Sunday that its recently developed Covid-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.</p>.<p>The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.</p>.<p>"The approval will have a positive impact on the company's performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.</p>.<p><strong>Also Read — <a href="https://www.deccanherald.com/business/business-news/softbank-plans-vision-fund-staff-cuts-of-at-least-20-1141638.html" target="_blank">SoftBank plans vision fund staff cuts of at least 20%</a></strong></p>.<p>The company cautioned, however, that it will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials.</p>.<p>China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's Covid-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.</p>.<p>Cansino also said it was uncertain when its vaccine would be able to go to market, since additional administrative approvals are still needed, while sales would depend on the Covid-19 situation at home and abroad, as well as China's vaccination rate.</p>.<p>China has seen a recent flare-up in Covid outbreaks. The southern tech hub of Shenzhen imposed a weekend lockdown in most parts of the city on Saturday, while the southwestern metropolis of Chengdu put its 21 million people under lockdown on Thursday.</p>.<p>Mainland China reported 1,848 new coronavirus cases for September 3, including both symptomatic and asymptomatic infections, compared with 1,988 new cases a day earlier.</p>